Karydas Daphne 4

What Happened

• Daphne Karydas, a director of Mineralys Therapeutics (MLYS), exercised stock options to acquire 3,000 shares at $12.02 per share (cost $36,060) and, on the same date (2026-06-17), sold 3,000 shares in an open-market transaction at $25.00 per share (gross proceeds $75,000). The Form 4 also reports a conversion/exercise of 3,000 shares listed with $0.00 consideration as disposed (as reported on the filing).

Key Details

• Transaction date: 2026-06-17.
• Option exercise (code M): 3,000 shares acquired at $12.02 each — $36,060 total.
• Open-market sale (code S): 3,000 shares sold at $25.00 each — $75,000 total.
• Additional exercise/conversion (code M) of 3,000 shares reported with $0.00 consideration (reported as disposed).
• Footnotes: Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted Dec 30, 2025 (F1). The reported stock option vests in 36 monthly installments beginning Oct 13, 2023 (F2).
• Shares owned after the transaction: not specified in the excerpt of the filing.
• Filing timeliness: report filed for the period/date 2026-06-17 (no late filing indicated in the report).

Context

• The sequence — exercising options and selling shares the same day — is commonly used to monetize vested options (often a cashless exercise/sale), but the filing shows these trades were made under a pre-established 10b5-1 plan. Derivative activity (code M) here means option exercise/conversion; the $0.00 line may reflect a separate conversion/withholding reporting detail included in the Form 4. As always, these transactions are factual disclosures and do not, by themselves, indicate the insider’s private view of the company.